Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dementia With Lewy Bodies (DLB)

Conditions

Dementia With Lewy Bodies (DLB)

Trial Timeline

Feb 1, 2011 โ†’ Apr 1, 2013

About Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo

Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo is a phase 3 stage product being developed by Eisai for Dementia With Lewy Bodies (DLB). The current trial status is completed. This product is registered under clinical trial identifier NCT01278407. Target conditions include Dementia With Lewy Bodies (DLB).

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01278407Phase 3Completed

Competing Products

20 competing products in Dementia With Lewy Bodies (DLB)

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 3
69
AL001 + Placebo + Open label - AL001AlectorPhase 3
69
AL001AlectorPhase 2
44
ATH-1017 + PlaceboLeonaBioPhase 2
44
IGC AD1 + PlaceboIGC PharmaPhase 1
25
E2020 + PlaceboEisaiApproved
85
ARICEPTEisaiPhase 3
77
RasagilineEisaiPhase 2
52
Donepezil HydrochlorideEisaiPre-clinical
23
donepezil hclEisaiPhase 3
77
E2020 + E2020EisaiPhase 2
52
donepezil hydrochloride (Aricept)EisaiApproved
85
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + PlaceboEisaiPhase 2
52
E2020 + E2020EisaiPhase 3
77
Irsenontrine + PlaceboEisaiPhase 2
52
E2020EisaiPhase 2
52
MecobalaminEisaiApproved
85
E2020 + PlaceboEisaiPhase 3
77
Donepezil HydrochlorideEisaiPhase 3
77
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved
85